Tumors as Organs: Biologically Augmenting Radiation Therapy by Inhibiting Transforming Growth Factor β Activity in Carcinomas
Tumors as Organs: Biologically Augmenting Radiation Therapy by Inhibiting Transforming Growth Factor β Activity in Carcinomas
复制标题
DOI：
10.1016/j.semradonc.2013.05.001
复制
发表时间：
2013-10-01
影响因子：
3.5
通讯作者：
Barcellos-Hoff, Mary Helen
中科院分区：
文献类型：
--
作者：
Du, Shisuo;Barcellos-Hoff, Mary Helen
转化生长因子β（TGF β）在调节正常器官中的多种生理过程中起关键作用，包括形态发生、胚胎发育、干细胞分化、免疫调节和伤口愈合。虽然被认为是肿瘤抑制因子，但TGF β是肿瘤微环境的关键介质，在肿瘤微环境中，它同样介导肿瘤和基质细胞表型、募集、炎症、免疫功能和血管生成。TGF β的活化是辐射组织中的早期和持续事件，并且TGF β信号传导控制有效的DNA损伤反应，这一事实提供了操纵肿瘤对辐射的反应的新手段。在这里，我们讨论了临床前研究揭开TGF β在癌症治疗中的作用，并回顾了肺癌中的TGF β生物学，作为TGF β通路抑制作为增强放射治疗的药物方法的机会的一个例子。Semin Radiat Oncol 23：242-251由Elsevier Inc.出版。
Transforming growth factor beta (TGF beta) plays critical roles in regulating a plethora of physiological processes in normal organs, including morphogenesis, embryonic development, stem cell differentiation, immune regulation, and wound healing. Though considered a tumor suppressor, TGF beta is a critical mediator of tumor microenvironment, in which it likewise mediates tumor and stromal cell phenotype, recruitment, inflammation, immune function, and angiogenesis. The fact that activation of TGF beta is an early and persistent event in irradiated tissues and that TGF beta signaling controls effective DNA damage response provides a new means to manipulate tumor response to radiation. Here we discuss preclinical studies unraveling TGF beta effects in cancer treatment and review TGF beta biology in lung cancer as an example of the opportunities for TGF beta pathway inhibition as a pharmaceutical approach to augment radiation therapy. Semin Radiat Oncol 23:242-251 Published by Elsevier Inc.